Eagle, Eli Lilly Drop Dueling Cancer Drug Patent Claims
Eagle Pharmaceuticals has agreed to drop its lingering antitrust claims over Eli Lilly's chemotherapy drug Alimta after the companies reached a settlement ending patent litigation and allowing Eagle to launch a...To view the full article, register now.
Already a subscriber? Click here to view full article